Found: 41
Select item for more details and to access through your institution.
Correction: Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group's clinical trial E3999.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00862-2
- By:
- Publication type:
- Article
Real‐world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower‐risk myelodysplastic syndromes.
- Published in:
- International Journal of Laboratory Hematology, 2021, v. 43, n. 3, p. 426, doi. 10.1111/ijlh.13400
- By:
- Publication type:
- Article
Allogeneic TCRαβ deficient CAR T-cells targeting CD123 in acute myeloid leukemia.
- Published in:
- Nature Communications, 2022, v. 13, n. 1, p. 1, doi. 10.1038/s41467-022-29668-9
- By:
- Publication type:
- Article
The therapeutic landscape for cells engineered with chimeric antigen receptors.
- Published in:
- Nature Biotechnology, 2020, v. 38, n. 2, p. 233, doi. 10.1038/s41587-019-0329-2
- By:
- Publication type:
- Article
Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML‐001.
- Published in:
- British Journal of Haematology, 2024, v. 204, n. 3, p. 877, doi. 10.1111/bjh.19202
- By:
- Publication type:
- Article
Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi‐centre setting.
- Published in:
- British Journal of Haematology, 2020, v. 190, n. 6, p. 891, doi. 10.1111/bjh.16594
- By:
- Publication type:
- Article
Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower‐intensity therapy: Roadmap from an ELN‐DAVID expert panel.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 12, p. 1847, doi. 10.1002/ajh.27087
- By:
- Publication type:
- Article
Long‐term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo‐controlled, phase 3 QUAZAR AML‐001 trial.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 4, p. E84, doi. 10.1002/ajh.26847
- By:
- Publication type:
- Article
Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells.
- Published in:
- Cytometry. Part A, 2015, v. 87, n. 4, p. 346, doi. 10.1002/cyto.a.22628
- By:
- Publication type:
- Article
Enasidenib for Relapsed/Refractory Acute Myeloid Leukemia With IDH2 Mutations: Optimizing the Patient Experience.
- Published in:
- Clinical Advances in Hematology & Oncology, 2018, v. 16, n. 5, p. 322
- By:
- Publication type:
- Article
Validation of International Working Group response criteria in higher‐risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium.
- Published in:
- Cancer Medicine, 2021, v. 10, n. 2, p. 447, doi. 10.1002/cam4.3608
- By:
- Publication type:
- Article
Comparison of Multiple Clinical Testing Modalities for Assessment of NPM1-Mutant AML.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.701318
- By:
- Publication type:
- Article
HIV/AIDS Case Histories: Diagnostic Problems.
- Published in:
- AIDS Patient Care & STDs, 1999, v. 13, n. 1, p. 57, doi. 10.1089/apc.1999.13.57
- By:
- Publication type:
- Article
Hepatitis C and B-Cell Lymphoma.
- Published in:
- AIDS Patient Care & STDs, 1998, v. 12, n. 8, p. 605, doi. 10.1089/apc.1998.12.605
- By:
- Publication type:
- Article
Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 6, p. 364, doi. 10.1016/j.clml.2024.01.007
- By:
- Publication type:
- Article
MDS-335: Ivosidenib (IVO) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome (R/R MDS): Updated Enrollment for the MDS Sub-Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S346, doi. 10.1016/S2152-2650(21)01805-X
- By:
- Publication type:
- Article
MDS-090: Phase II Study of the IDH2 Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S339, doi. 10.1016/S2152-2650(21)01791-2
- By:
- Publication type:
- Article
Poster: MDS-335: Ivosidenib (IVO) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome (R/R MDS): Updated Enrollment for the MDS Sub-Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S230, doi. 10.1016/S2152-2650(21)01451-8
- By:
- Publication type:
- Article
Poster: MDS-090: Phase II Study of the IDH2 Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S226, doi. 10.1016/S2152-2650(21)01427-0
- By:
- Publication type:
- Article
Ivosidenib (IVO; AG-120) in IDH1-Mutant Newly-Diagnosed Acute Myeloid Leukemia (ND AML): Updated Results from a Phase 1 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S220, doi. 10.1016/j.clml.2019.07.094
- By:
- Publication type:
- Article
Ivosidenib (AG-120) in Mutant IDH1 Relapsed/Refractory Acute Myeloid Leukemia: Results of a Phase 1 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S204, doi. 10.1016/j.clml.2018.07.057
- By:
- Publication type:
- Article
Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group's clinical trial E3999.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 9, p. 1, doi. 10.1038/s41408-022-00736-z
- By:
- Publication type:
- Article
IDH2 mutations in patients with normal karyotype AML predict favorable responses to daunorubicin, cytarabine and cladribine regimen.
- Published in:
- Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-88120-y
- By:
- Publication type:
- Article
Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia.
- Published in:
- Clinical Epigenetics, 2019, v. 11, n. 1, p. N.PAG, doi. 10.1186/s13148-019-0704-3
- By:
- Publication type:
- Article
A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemia.
- Published in:
- Hematological Oncology, 2023, v. 41, n. 4, p. 743, doi. 10.1002/hon.3159
- By:
- Publication type:
- Article
Oral Azacitidine (Oral-AZA) in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC): Long-Term Overall Survival (OS) Results from the Phase 3 QUAZAR AML-001 Trial.
- Published in:
- Journal of Oncology Navigation & Survivorship, 2022, v. 13, n. 11, p. 378
- By:
- Publication type:
- Article
Are We Ready for Precision Medicine in Acute Myeloid Leukemia?
- Published in:
- Clinical Advances in Hematology & Oncology, 2016, v. 14, n. 8, p. 582
- By:
- Publication type:
- Article
Evolving Treatments in Acute Myeloid Leukemia.
- Published in:
- Clinical Advances in Hematology & Oncology, 2015, v. 13, n. 2, p. 93
- By:
- Publication type:
- Article
Treating Relapsed/Refractory ALL in Older Patients: Case Presentations.
- Published in:
- Clinical Advances in Hematology & Oncology, 2014, v. 12, n. 12, p. 11
- By:
- Publication type:
- Article
Low clinical trial accrual of patients with myelodysplastic syndromes: Causes and potential solutions.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia.
- Published in:
- 2018
- By:
- Publication type:
- journal article
The effect of initial molecular profile on response to recombinant interferon-α (rIFNα) treatment in early myelofibrosis.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: A report on behalf of the MDS Clinical Research Consortium.
- Published in:
- Cancer (0008543X), 2015, v. 121, n. 6, p. 876, doi. 10.1002/cncr.29145
- By:
- Publication type:
- Article
Arsenic Trioxide and Low-dose Cytarabine in Older Patients With Untreated Acute Myeloid Leukemia, Excluding Acute Promyelocytic Leukemia.
- Published in:
- Cancer (0008543X), 2008, v. 113, n. 9, p. 2504, doi. 10.1002/cncr.23855
- By:
- Publication type:
- Article
Epidermal Growth Factor and Basic Fibroblast Growth Factor Have Independent Actions on Mesencephalic Dopamine Neurons in Culture.
- Published in:
- Journal of Neurochemistry, 1994, v. 62, n. 6, p. 2166, doi. 10.1046/j.1471-4159.1994.62062166.x
- By:
- Publication type:
- Article
Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial.
- Published in:
- Journal of Hematology & Oncology, 2021, v. 14, n. 1, p. 1, doi. 10.1186/s13045-021-01142-x
- By:
- Publication type:
- Article
Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial.
- Published in:
- Journal of Hematology & Oncology, 2021, v. 14, n. 1, p. 1, doi. 10.1186/s13045-020-01004-y
- By:
- Publication type:
- Article
Low participation rates and disparities in participation in interventional clinical trials for myelodysplastic syndromes.
- Published in:
- 2020
- By:
- Publication type:
- journal article
The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Diagnostic and molecular testing patterns in patients with newly diagnosed acutemyeloid leukemia in the Connect® MDS/AML Disease Registry.
- Published in:
- EJHaem, 2020, v. 1, n. 1, p. 1, doi. 10.1002/jha2.16
- By:
- Publication type:
- Article
Standardizing the Initial Evaluation for Myelodysplastic Syndromes.
- Published in:
- Current Hematologic Malignancy Reports, 2013, v. 8, n. 4, p. 361, doi. 10.1007/s11899-013-0180-3
- By:
- Publication type:
- Article